Morningstar brands and products Company Portfolio ...

In Europe, CARMAT secured CE Mark approval for Aeson in December as a transplant-bridging device, and is preparing for commercial launches, initially in Germany.

of an article on the performance of Aeson® total artificial heart in treating heart failure patients with pulmonary hypertension. PARIS, January 29, 2025--Regulatory News: CARMAT (FR0010907956 ...

Stéphane Piat, Chief Executive Officer of CARMAT, stated: “With 42 implants of our Aeson® artificial heart and €7 million in sales, i.e. 2.5 times higher than in 2023, we delivered a very ...

of an article on the performance of Aeson® total artificial heart in treating heart failure patients with pulmonary hypertension. PARIS, January 29, 2025--Regulatory News: CARMAT (FR0010907956, ALCAR) ...

CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company’s ambition is to make Aeson® the first alternative to a heart transplant, and thus ...

This highly encouraging momentum supports CARMAT's ambition to double sales in 2025, and gradually establish Aeson® as a benchmark therapy for the treatment of advanced heart failure.